COVID-19 Journal Publications

This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. The list of publications below is limited to products that have either have received emergency use authorization and/or have been approved for marketed use and may contain information about doses, uses, formulations and populations different from product labeling. Please refer to the product’s Fact Sheets and/or Full Prescribing Information in the provided link.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services below for further assistance.

bamlanivimab

HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

Bamlanivimab has not been approved, but has been authorized for emergency use by FDA, to treat mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization*.* Bamlanivimab is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.

bamlanivimab and etesivimab

HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

Bamlanivimab and Etesevimab together is authorized for use under an Emergency Use Authorization for the treatment of mild to moderate COVID-19 illness in adults and pediatric patients 12 years and older, who weigh at least 40 kg, who are at high risk for progressing to severe COVID-19 illness and/or hospitalization. Bamlanivimab and Etesevimab together is an investigational drug that has not been approved by the FDA for any use. It is not yet known if bamlanivimab and etesevimab together is safe and effective for the treatment of COVID-19. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless the authorization is terminated or revoked sooner.


Contact Lilly

Call Us

If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.

Daily Live Support: 9am to 7pm ET.
After Hours: Call Back Support Available

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical